Actinium is a radioactive metallic element, atomic number 89, that sits at the very beginning of the actinide series in the periodic table. For most of its history since André-Louis Debierne first isolated it from uranium ore in 1899, actinium was little more than a scientific curiosity, too scarce and too radioactive to find practical use. That has changed dramatically in recent years: one of its isotopes, actinium-225, has emerged as a leading candidate for a form of cancer treatment called targeted alpha therapy, and the scramble to produce enough of it is reshaping nuclear medicine logistics worldwide.
Basic Properties and Why Actinium Is Hard to Study
Actinium is a soft, silvery-white metal that glows faintly blue in the dark because its intense radioactivity excites the surrounding air. It has no stable isotopes. Every form of it decays, which means any sample you collect is actively disappearing. In nature, actinium exists in vanishingly small quantities, produced as a trace byproduct of the decay of uranium and thorium in the Earth’s crust. Its rarity and radioactivity together made it one of the least-studied elements on the periodic table for over a century.
Because so little actinium can be accumulated at once, basic chemical measurements that are routine for most elements have required creative experimental approaches. Researchers only recently characterized the actinium aquo ion, finding that about 11 water molecules coordinate directly around a dissolved actinium ion at a distance of roughly 2.63 angstroms. That measurement matters because understanding how actinium behaves in solution is essential for designing molecules that can hold onto it tightly enough to use in medicine.
1ACS Central Science. Synthesis and Characterization of the Actinium Aquo IonTheoretical studies of the actinium-actinium bond in diatomic molecules show that bonding in actinium relies primarily on its 6d, 7s, and 7p orbitals, with the 5f orbitals playing a much smaller role than they do in heavier actinides like uranium. This makes actinium’s bonding character somewhat more like that of the transition metals than like its heavier actinide cousins, a quirk that has practical consequences for the chemistry of holding it inside a drug molecule.
2PubMed. Exploring the actinide-actinide bond: theoretical studies of the chemical bond in Ac2, Th2, Pa2, and U2Key Isotopes and Their Decay
Actinium has over 30 known isotopes, but two stand out for practical importance. Actinium-227, the longest-lived isotope, has a half-life of about 21.8 years. It occurs naturally as part of the uranium-235 decay chain and was historically the isotope most associated with the element. Researchers have measured actinium-227 in ocean water across locations from the Southeast Pacific to the Central Arctic, using it as a tracer to study deep-sea mixing and circulation patterns.
3Earth and Planetary Science Letters. Actinium-227 as a deep-sea tracer: sources, distribution and applicationsActinium-225, with a half-life of about 10 days, is the isotope driving most of the current excitement. When it decays, it releases four alpha particles through a cascade of daughter nuclides before arriving at stable bismuth-209. That cascade is what makes it so potent for cancer therapy and so challenging to work with. Researchers have systematically studied the decay chains of radioactive actinium isotopes, comparing half-lives of different decay modes to map out the full picture of how each isotope transforms.
4International Journal of Modern Physics E. A study of decay chains of radioactive actinium isotopesWhy Actinium-225 Matters for Cancer Treatment
The medical interest in actinium-225 centers on a concept called targeted alpha therapy. Alpha particles are heavy, positively charged chunks of matter ejected during radioactive decay. They travel only a tiny distance through tissue, on the order of a few cell widths, but deposit enormous energy along that short path. That combination makes them ideal for killing cancer cells while largely sparing surrounding healthy tissue, at least in principle.
Targeted alpha therapy has shown greater effectiveness than beta radiation at destroying cancer cells, largely because the dense energy deposited by alpha particles overwhelms a cell’s ability to repair its DNA. The biological damage comes from both the direct hits to DNA strands and the flood of reactive oxygen and nitrogen species generated in the immediate vicinity.
5PubMed. Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapyThe basic strategy is to attach actinium-225 to a molecule that seeks out cancer cells, inject it into the patient, and let the alpha emissions do their work right at the tumor site. Since actinium-225 generates four alpha particles as it decays through its daughter chain, a single atom delivers far more cell-killing energy than an isotope that emits just one. Actinium-225 can be used directly on targeting molecules or can serve as a generator source for bismuth-213, another short-lived alpha emitter used in therapy.
6PubMed Central. Actinium-225 targeted alpha particle therapy for prostate cancerThe Daughter Recoil Problem
The same decay chain that makes actinium-225 so powerful also creates a serious engineering problem. Each time an alpha particle flies out of the nucleus, the remaining daughter atom recoils in the opposite direction with an energy of roughly 100 to 200 keV. That recoil energy is orders of magnitude higher than the energy of any chemical bond, so the daughter atom breaks free from whatever molecule was holding the parent actinium in place.
7Scientific Reports. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrierOnce freed, those radioactive daughters can travel through the body and deposit alpha radiation in healthy organs. This redistribution of daughter nuclides is one of the central challenges in the field. There is no chemical trick that can hold the daughters in place through the recoil event, because the physics simply overwhelms the chemistry. Researchers are exploring encapsulation strategies and nanoparticle carriers that might physically trap the daughters, but no perfect solution exists yet. The problem is particularly acute for therapies against diffuse cancers like leukemia, where the drug circulates throughout the bloodstream and freed daughters have easy access to sensitive organs.
8PubMed Central. Actinium-225 targeted alpha particle therapy for prostate cancerHolding Actinium in Place With Chelators
Even though the daughters escape after the first alpha decay, you still need the parent actinium-225 itself to stay firmly attached to the targeting molecule for as long as possible. If free actinium-225 leaks out of the drug before reaching the tumor, it accumulates in bones and liver, causing serious toxicity. In mice, unchelated free actinium-225 delivered a liver radiation dose up to 200 times higher than the same amount of actinium properly bound to a chelating molecule.
9PubMed. In vivo Evaluation of Free and Chelated Accelerator-produced Actinium-225 – Radiation Dosimetry and Toxicity ResultsDesigning chelators for actinium-225 is unusually difficult. Actinium is the largest trivalent ion among the actinides, and its coordination chemistry was poorly understood for decades. Standard chelators used for other medical radiometals tend to let actinium slip out over time. A significant advance came with the development of macropa, an 18-membered macrocyclic ligand that binds actinium-225 rapidly at room temperature and holds it with remarkable stability. In laboratory tests, the actinium-macropa complex remained intact for over a week when exposed to excess competing metal ions or human serum.
10PubMed. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha TherapyBuilding on macropa, researchers have created modified versions with added benzene rings in the macrocyclic core to make the structure more rigid, aiming for even better stability and easier attachment to antibodies and other targeting molecules.
11PubMed Central. H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha TherapyOne practical advantage of macropa is that radiolabeling happens in minutes at room temperature. Older chelators often required heating, which can damage sensitive biological molecules like antibodies. The ability to label quickly and gently opens up the use of larger, more fragile targeting agents that would not survive harsher conditions.
Clinical Results So Far
The most advanced clinical work with actinium-225 has focused on metastatic prostate cancer. Agents like actinium-225-labeled PSMA-617 target a protein on the surface of prostate cancer cells. A systematic review and meta-analysis of these treatments found that roughly two-thirds of patients achieved at least a 50% drop in PSA levels, a key marker of disease response. Side effects were mostly mild, though anemia occurred in about 11% of patients and low platelet counts in about 6%.
12PubMed Central. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer – a systematic review and meta-analysisThese results are striking because the patients involved were typically heavily pre-treated, meaning they had already failed multiple rounds of other therapies. Imaging studies showed actual shrinkage or disappearance of cancer lesions on PET/CT scans, not just changes in blood markers. However, dry mouth from salivary gland damage, kidney stress, and blood count drops remain the primary safety concerns, and researchers are actively working on dosing strategies and protective protocols to manage them.
13PubMed Central. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer ManagementBeyond prostate cancer, actinium-225 has been tested against acute myeloid leukemia using an antibody called lintuzumab that targets the CD33 protein found on leukemia cells. In a first-in-human phase I trial, the treatment eliminated circulating leukemia cells from the blood in about 63% of evaluable patients and reduced bone marrow blasts in about 67%, with some patients achieving near-complete clearance of leukemia from the marrow.
14PubMed Central. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-LintuzumabThe Supply Problem
Perhaps the biggest bottleneck for actinium-225-based therapies is simply getting enough of it. The world’s supply has historically come from a handful of aging stocks of thorium-229, itself a decay product of uranium-233 that was produced during Cold War-era nuclear programs. These stockpiles are finite and shrinking. The total amount of actinium-225 available from these legacy sources falls far short of what would be needed if any of the therapies under development reached widespread clinical use.
The most widely pursued alternative is bombardment of thorium-232 targets with high-energy protons from particle accelerators. This spallation approach can produce actinium-225 along with other useful isotopes like radium-223 (already approved for treating bone metastases) and radium-225, which itself decays into actinium-225 and can serve as a generator source of isotopically pure material.
15PubMed. Study of medical radioisotope production of Ac-225 by proton acceleratorSeparating actinium-225 from an irradiated thorium target is a complex radiochemistry challenge in its own right. Canadian Nuclear Laboratories developed a separation scheme using ion exchange and extraction chromatography that can yield up to about 100 millicuries of pure actinium-225 per year from a single thorium source.
16PubMed. Construction of a thorium/actinium generator at the Canadian Nuclear LaboratoriesBecause the targets are intensely radioactive after irradiation, all of this work has to happen inside shielded hot cells using robotic manipulators. Researchers have developed automated systems that can run the entire separation and purification process remotely, handling the chemistry without any direct human contact with the material.
17Separation and Purification Technology. Automated preparation of Actinium-225 with accelerator-based production from irradiated natural thorium targetsActinium-227 as an Ocean Tracer
While actinium-225 dominates the medical conversation, its longer-lived sibling actinium-227 has carved out a niche in oceanography. With its 21.8-year half-life, actinium-227 sits in a useful sweet spot: long enough to track water-mass movements over years and decades, short enough that its concentrations carry meaningful information about how quickly deep water mixes with surface layers.
Actinium-227 enters the ocean primarily from the decay of protactinium-231 in deep-sea sediments. It then dissolves into the bottom water and gets carried along with ocean currents, gradually decaying as it goes. By measuring its concentration at different depths and locations, oceanographers can calculate rates of vertical mixing in the deep ocean. Measurements have been taken across the Southeast Pacific, Central Arctic, Antarctic Circumpolar Current, and Weddell Gyre, building a picture of deep-water circulation that complements data from other chemical tracers.
18Earth and Planetary Science Letters. Actinium-227 as a deep-sea tracer: sources, distribution and applicationsMeasuring actinium-227 in seawater is analytically demanding because concentrations are extremely low. Newer methods using isotope dilution and mass spectrometry have improved sensitivity and precision, allowing researchers to detect actinium in freshwater samples as well, which opens up applications in studying groundwater discharge into coastal zones and rivers.
Handling Actinium Safely
Working with actinium in any form requires serious radiation protection infrastructure. Alpha particles themselves are stopped by a sheet of paper or the outer layer of skin, so external exposure is less of a concern than with gamma-emitting isotopes. The real danger is internal contamination: if actinium is inhaled, ingested, or enters through a wound, its alpha emissions can cause devastating local damage to tissue. The daughter nuclides scattered throughout the decay chain include gamma emitters as well, so shielded enclosures remain necessary.
The toxicity difference between chelated and free actinium underscores why the chemistry of containment matters so much. In animal studies, unchelated actinium-225 concentrated heavily in the liver, delivering radiation doses hundreds of times higher than the same quantity bound to a chelator like DOTA.
19PubMed. In vivo Evaluation of Free and Chelated Accelerator-produced Actinium-225 – Radiation Dosimetry and Toxicity ResultsFor production facilities, the practical consequence is that every step of target processing, chemical separation, and drug formulation must happen behind heavy shielding with remote-controlled equipment. Even small spills can create contamination problems that are difficult to clean up, because actinium’s daughter products include radon-like gases that can spread through ventilation systems. The investment required in specialized infrastructure is part of what makes scaling up actinium-225 production so expensive and slow, even when the underlying chemistry is well understood.